Related Experiment Video
Updated: May 22, 2025
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
9.7K
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Peter L Greenberg1, Richard M Stone2, Yasmin Abaza3
1Stanford Cancer Institute.
Journal of the National Comprehensive Cancer Network : JNCCN
|March 12, 2025
Summary
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) offer updated care recommendations. These insights cover new treatments for lower-risk and higher-risk MDS, plus emerging therapeutic agents.
Area of Science:
- Hematology
- Oncology
- Clinical Guidelines
Background:
- Myelodysplastic Syndromes (MDS) require updated management strategies.
- Recent clinical evidence has significantly advanced MDS treatment and understanding of prognostic factors.
Purpose of the Study:
- To present the latest NCCN Guidelines for Myelodysplastic Syndromes (MDS).
- To summarize recent evidence impacting MDS evaluation, diagnosis, and comprehensive patient care.
Main Methods:
- Annual review of emerging clinical evidence and biologic factors by a multidisciplinary panel of MDS experts.
- Evaluation of new data to inform treatment recommendations and prognostic significance.
Main Results:
- Updated treatment recommendations for both lower-risk and higher-risk MDS.
- Preference stratification of therapeutic agents based on new evidence.
- Inclusion of emerging data on novel therapeutics.
Conclusions:
- The NCCN Guidelines provide current, evidence-based recommendations for MDS management.
- The updates reflect significant advances in understanding and treating MDS.
- Expert consensus guides the integration of novel therapies into clinical practice.
